Zalgen to provide test kits for Lassa fever study in West Africa

LabPulse.com staff writers
Aug 25, 2021
2020 04 04 00 34 1763 Lab Test Antibody 400

Zalgen Labs has inked a three-year contract with the Coalition for Epidemic Preparedness Innovations (CEPI) to provide its antibody testing kits for a study to assess the incidence of Lassa fever infections in West Africa.

Under the terms of the contract, Zalgen will supply its Lassa fever antibody testing kits (ReLASV Pan-Lassa NP IgG ELISA) to CEPI's Enable study partners in Benin, Guinea, Liberia, Nigeria, and Sierra Leone, to test up to 7,000 participants for Lassa fever antibodies, specifically the anti-Lassa virus nucleoprotein human immunoglobulin G (IgG) antibodies.

CEPI, a global health organization, represents a partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines against future epidemics.

Latest in Fever
2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400
Universal COVID-19 testing advised for long-term care facilities
July 14, 2020
2020 03 18 22 45 6099 2020 03 19 Genital Pathology 20200318221617
Pathologists advance understanding of deadly female genital tract infections
March 18, 2020
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2019 05 14 20 33 2364 Ixodes Scapularis Tick 400
Point-of-care test for lethal spotted fever infections in the pipeline
January 20, 2020
Related Stories
2020 08 27 17 11 6347 Infectious Diseases Research 400
Valley Fever
NIH establishes Centers for Research in Emerging Infectious Diseases
2020 05 05 20 14 4391 Eu Flag European Commission Brussels 400
Research Alliance
Europe raises 7.4B euros for coronavirus response
2020 02 08 00 11 9942 Virus Coronavirus 400
Research Alliance
WHO steps on the gas for collaboration on treatments and tests
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Fever
Universal COVID-19 testing advised for long-term care facilities
By Leah Sherwood
At the start of the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention (CDC) recommended that only patients who exhibited symptoms consistent with COVID-19 (such as fever, cough, and other respiratory symptoms) should be tested for the disease. However, long-term care facilities have been a hot spot for SARS-CoV-2 infections, and mortality rates have remained high.
July 14, 2020
2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400
Pathologists advance understanding of deadly female genital tract infections
By Emily Hayes
Group A strep is typically found in the mouth, but it can also infect other mucosal areas of the body, with deadly results. The researchers noted that GAS surface proteins cause an estimated 700 million human infections annually around the world, including 15 million in the U.S. GAS is at the root of puerperal sepsis (also known as childbed fever), which is the leading cause of maternal deaths, and it causes necrotizing myometritis (inflammation of the uterine myometrium) as well as severe infections in newborns.
March 18, 2020
2020 03 18 22 45 6099 2020 03 19 Genital Pathology 20200318221617
Innovation in tests for spotted fever, TB | Guidance on breast cancer testing | What's next for PacBio and Illumina?
By Emily Hayes
Dear LabPulse Member,
January 20, 2020
Point-of-care test for lethal spotted fever infections in the pipeline
By Emily Hayes
The biomarker is the putative N-acetylmuramoyl-L-alanine amidase RC0497, a protein that was identified through an analysis of human umbilical vein endothelial cells infected with the bacterial pathogen Rickettsia conorrii. A blood test for the protein was successfully tested in a mouse model and in serum samples taken from infected humans, co-lead investigator Yingxin Zhao, PhD, a scientist at the Sealy Center for Molecular Medicine, University of Texas Medical Branch (UTMB), and colleagues reported.
January 20, 2020
2019 05 14 20 33 2364 Ixodes Scapularis Tick 400
Inflammatix scores BARDA contract for infection tests
By LabPulse.com staff writers
Burlingame, CA-based Inflammatix developed the HostDx multiplex isothermal platform for mRNA testing at the point of care, with results available in less than 30 minutes. BARDA is part of the U.S. Department of Health and Human Services.
November 13, 2019
2019 11 14 01 22 8300 Inflammatix Host Dx Fever 20191114011003
IGeneX reports data for tick-borne fever test
By LabPulse.com staff writers
Tick-borne relapsing fever and Lyme disease (LD) are caused by two related Borrelia bacteria groups, each of which includes more than 20 species.
October 29, 2019
2019 07 11 23 25 7135 Ticks Sign 400
IGeneX survey flags gaps in tick-borne disease testing
By LabPulse.com staff writers
The survey of 198 patients/customers tested between 2018 and 2019 highlights the challenges of getting a professional to make a diagnosis, as well as the financial impact of a delayed diagnosis, according to the company. IGeneX markets tests for Lyme disease, relapsing fever, babesiosis, and other conditions caused by ticks.
July 10, 2019
2019 07 11 00 43 8031 Question Mark Magnifying 400
Page 1 of 1